

July 26, 2013

**For Immediate Release**

Company name           Otsuka Holdings Co., Ltd.  
 Representative        Tatsuo Higuchi  
                               President and Representative Director, CEO  
 Code number         4578 First Section , Tokyo Stock Exchange  
 Inquiries             Takuma Kimura  
                               Director, Investors Relations Department

**Otsuka announces 2013 second quarter U.S. net sales figures of ABILIFY®**

Tokyo Japan – Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi, "Otsuka Holdings") announces 2013 second quarter U.S. net sales\*<sup>1</sup> figures of ABILIFY (aripiprazole), the antipsychotic agent discovered and marketed worldwide by its wholly owned direct subsidiary Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical").

\*<sup>1</sup> Net sales in U.S. and Puerto Rico

ABILIFY is promoted in the U.S. by Otsuka America Pharmaceutical, Inc. ("OAPI," a wholly owned subsidiary of Otsuka America, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical) based on the collaboration agreement with Bristol-Myers Squibb. Net sales of ABILIFY is reported to OAPI; Otsuka Pharmaceutical pays Bristol-Myers Squibb a fee based on the agreement. 2013 second quarter U.S. net sales of ABILIFY reported to OAPI is \$1,170 million.

**【OAPI U.S. Net Sales Figure of ABILIFY】**

(\$ in millions)	1 <sup>st</sup> Qtr	2 <sup>nd</sup> Qtr	3 <sup>rd</sup> Qtr	4 <sup>th</sup> Qtr	Year
2013	984	1,170*			2,154*
% change	9.8%	9.5%			9.7%
2012	896	1,068	1,015	1,230	4,208
% change	-0.1%	6.3%	3.3%	14.3%	6.3%

\* unaudited

The consolidated business forecast of fiscal 2013 announced by Otsuka Holdings on May 14, 2013 will not be changed.

**About ABILIFY:**

Discovered by Otsuka Pharmaceutical, ABILIFY is the first and only available dopamine partial agonist and is indicated for the treatment of multiple neurological disorders.

To date, ABILIFY is sold in over 60 countries and regions worldwide including Japan with global sales of 438.5 billion yen in fiscal 2012 accounting for 36% of Otsuka Holdings' consolidated results.

**About Otsuka Group:**

The Otsuka Group is a diversified healthcare group operating globally under the corporate philosophy "Otsuka-people creating new products for better health worldwide". The Otsuka Group has business operations in 26 countries and regions around the world, and its consolidated sales for fiscal 2012 is ¥1,218.1 billion.